Nanotechnology applications in hematological malignancies (Review)

Samir,Ahmed; Elgamal,Basma M.; Gabr,Hala; Sabaawy,Hatem E.

doi:10.3892/or.2015.4100

Nanotechnology applications in hematological malignancies (Review)

Authors:
- Ahmed Samir
- Basma M. Elgamal
- Hala Gabr
- Hatem E. Sabaawy
View Affiliations

Affiliations: Department of Clinical Pathology, National Cancer Institute, Cairo University, Cairo, Egypt, Department of Clinical Pathology, Kasr Al‑Ainy Faculty of Medicine, Cairo University, Cairo, Egypt
Published online on: July 2, 2015 https://doi.org/10.3892/or.2015.4100
Pages: 1097-1105

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A major limitation to current cancer therapies is the development of therapy-related side-effects and dose limiting complications. Moreover, a better understanding of the biology of cancer cells and the mechanisms of resistance to therapy is rapidly developing. The translation of advanced knowledge and discoveries achieved at the molecular level must be supported by advanced diagnostic, therapeutic and delivery technologies to translate these discoveries into useful tools that are essential in achieving progress in the war against cancer. Nanotechnology can play an essential role in this aspect providing a transforming technology that can translate the basic and clinical findings into novel diagnostic, therapeutic and preventive tools useful in different types of cancer. Hematological malignancies represent a specific class of cancer, which attracts special attention in the applications of nanotechnology for cancer diagnosis and treatment. The aim of the present review is to elucidate the emerging applications of nanotechnology in cancer management and describe the potentials of nanotechnology in changing the key fundamental aspects of hematological malignancy diagnosis, treatment and follow-up.

View Figures

View References

1	Feynman R: There's plenty of room at the bottom: An invitation to enter a new field of physics. Caltech Engineering and Science. 23(5): 22–36. 1959.
2	Jain KK: Introduction to nanomedicine. The handbook of nanomedicine. Jain KK: Hamana press; pp. 1–5. 2008, View Article : Google Scholar
3	Ren Y, Zhang H, Chen B, Cheng J, Cai X, Liu R, Xia G, Wu W, Wang S, Ding J, et al: Multifunctional magnetic Fe₃O₄ nanoparticles combined with chemotherapy and hyperthermia to overcome multidrug resistance. Int J Nanomed. 7:2261–2269. 2012.
4	Fakruddin M, Hossain Z and Afroz H: Prospects and applications of nanobiotechnology: A medical perspective. J Nanobiotechnol. 10:312012. View Article : Google Scholar
5	Kim ES, Ahn EH, Chung E and Kim DH: Recent advances in nanobiotechnology and high-throughput molecular techniques for systems biomedicine. Mol Cells. 36:477–484. 2013. View Article : Google Scholar : PubMed/NCBI
6	Cai W, Gao T, Hong H and Sun J: Applications of gold nanoparticles in cancer nanotechnology. Nanotechnol Sci Appl. 1:17–32. 2008.PubMed/NCBI
7	Bharali DJ and Mousa SA: Emerging nanomedicines for early cancer detection and improved treatment: Current perspective and future promise. Pharmacol Ther. 128:324–335. 2010. View Article : Google Scholar : PubMed/NCBI
8	Jiang W, Kim BY, Rutka JT and Chan WC: Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol. 3:145–150. 2008. View Article : Google Scholar : PubMed/NCBI
9	Geng Y, Dalhaimer P, Cai S, Tsai R, Tewari M, Minko T and Discher DE: Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol. 2:249–255. 2007. View Article : Google Scholar
10	Verma A and Stellacci F: Effect of surface properties on nanoparticle-cell interactions. Small. 6:12–21. 2010. View Article : Google Scholar
11	Olsen RJ, Chang CC, Herrick JL, Zu Y and Ehsan A: Acute leukemia immunohistochemistry: A systematic diagnostic approach. Arch Pathol Lab Med. 132:462–475. 2008.PubMed/NCBI
12	Ferrara F and Schiffer CA: Acute myeloid leukaemia in adults. Lancet. 381:484–495. 2013. View Article : Google Scholar : PubMed/NCBI
13	Inaba H, Greaves M and Mullighan CG: Acute lymphoblastic leukaemia. Lancet. 381:1943–1955. 2013. View Article : Google Scholar : PubMed/NCBI
14	Salem DA and Abd El-Aziz SM: Flowcytometric immunopheno-typic profile of acute leukemia: Mansoura experience. Indian J Hematol Blood Transfus. 28:89–96. 2012. View Article : Google Scholar :
15	Sefah K, Tang ZW, Shangguan DH, Chen H, Lopez-Colon D, Li Y, Parekh P, Martin J, Meng L, Phillips JA, et al: Molecular recognition of acute myeloid leukemia using aptamers. Leukemia. 23:235–244. 2009. View Article : Google Scholar : PubMed/NCBI
16	Yang M, Jiang G, Li W, Qiu K, Zhang M, Carter CM, Al-Quran SZ and Li Y: Developing aptamer probes for acute myelogenous leukemia detection and surface protein biomarker discovery. J Hematol Oncol. 7:52014. View Article : Google Scholar : PubMed/NCBI
17	Mallikaratchy PR, Ruggiero A, Gardner JR, Kuryavyi V, Maguire WF, Heaney ML, McDevitt MR, Patel DJ and Scheinberg DA: A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia. Nucleic Acids Res. 39:2458–2469. 2011. View Article : Google Scholar :
18	Lakhin AV, Tarantul VZ and Gening LV: Aptamers: Problems, solutions and prospects. Acta Naturae. 5:34–43. 2013.
19	Herr JK, Smith JE, Medley CD, Shangguan D and Tan W: Aptamer-conjugated nanoparticles for selective collection and detection of cancer cells. Anal Chem. 78:2918–2924. 2006. View Article : Google Scholar : PubMed/NCBI
20	Shook D, Coustan-Smith E, Ribeiro RC, Rubnitz JE and Campana D: Minimal residual disease quantitation in acute myeloid leukemia. Clin Lymphoma Myeloma. 9(Suppl 3): S281–S285. 2009. View Article : Google Scholar : PubMed/NCBI
21	Campana D and Coustan-Smith E: Measurements of treatment response in childhood acute leukemia. Korean J Hematol. 47:245–254. 2012. View Article : Google Scholar
22	Campana D: Minimal residual disease in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2010:7–12. 2010. View Article : Google Scholar
23	Jaetao JE, Butler KS, Adolphi NL, Lovato DM, Bryant HC, Rabinowitz I, Winter SS, Tessier TE, Hathaway HJ, Bergemann C, et al: Enhanced leukemia cell detection using a novel magnetic needle and nanoparticles. Cancer Res. 69:8310–8316. 2009. View Article : Google Scholar : PubMed/NCBI
24	Pillai JJ, Thulasidasan AK, Anto RJ, Chithralekha DN, Narayanan A and Kumar GS: Folic acid conjugated cross-linked acrylic polymer (FA-CLAP) hydrogel for site specific delivery of hydrophobic drugs to cancer cells. J Nanobiotechnol. 12:252014. View Article : Google Scholar
25	Davis T and Farag SS: Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: Liposome-encapsulated vincristine. Int J Nanomed. 8:3479–3488. 2013.
26	Krishnan V, Xu X, Barwe SP, Yang X, Czymmek K, Waldman SA, Mason RW, Jia X and Rajasekaran AK: Dexamethasone-loaded block copolymer nanoparticles induce leukemia cell death and enhance therapeutic efficacy: A novel application in pediatric nanomedicine. Mol Pharm. 10:2199–2210. 2013. View Article : Google Scholar
27	Rahman HS, Rasedee A, How CW, Abdul AB, Zeenathul NA, Othman HH, Saeed MI and Yeap SK: Zerumbone-loaded nanostructured lipid carriers: Preparation, characterization, and antileukemic effect. Int J Nanomed. 8:2769–2781. 2013. View Article : Google Scholar
28	Cosco D, Rocco F, Ceruti M, Vono M, Fresta M and Paolino D: Self-assembled squalenoyl-cytarabine nanostructures as a potent nanomedicine for treatment of leukemic diseases. Int J Nanomed. 7:2535–2546. 2012.
29	Lai BB, Chen BA, Cheng J, Gao F, Xu WL, Ding JH, Gao C, Sun XC, Li GH, Chen WJ, et al: Daunorubicin-loaded magnetic nanoparticles of Fe₃O₄ greatly enhance the responses of multi-drug-resistant K562 leukemic cells in a nude mouse xenograft model to chemotherapy. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 17:345–351. 2009.PubMed/NCBI
30	He Q, Gao Y, Zhang L, Zhang Z, Gao F, Ji X, Li Y and Shi J: A pH-responsive mesoporous silica nanoparticles-based multi-drug delivery system for overcoming multi-drug resistance. Biomaterials. 32:7711–7720. 2011. View Article : Google Scholar : PubMed/NCBI
31	De Boer AB, De Lange EL, Van der Sandt IC and Breimer DD: Transporters and the blood-brain barrier (BBB). Int J Clin Pharmacol Ther. 36:14–15. 1998.PubMed/NCBI
32	Cianfriglia M: Targeting MDR1-P-glycoprotein (MDR1-Pgp) in immunochemotherapy of acute myeloid leukemia (AML). Ann Ist Super Sanita. 49:190–208. 2013.PubMed/NCBI
33	Chen B, Sun Q, Wang X, Gao F, Dai Y, Yin Y, Ding J, Gao C, Cheng J, Li J, et al: Reversal in multidrug resistance by magnetic nanoparticle of Fe₃O₄ loaded with adriamycin and tetrandrine in K562/A02 leukemic cells. Int J Nanomed. 3:277–286. 2008.
34	Chen BA, Lai BB, Cheng J, Xia GH, Gao F, Xu WL, Ding JH, Gao C, Sun XC, Xu CR, et al: Daunorubicin-loaded magnetic nanoparticles of Fe₃O₄ overcome multidrug resistance and induce apoptosis of K562-n/VCR cells in vivo. Int J Nanomed. 4:201–208. 2009. View Article : Google Scholar
35	Janko C, Dürr S, Munoz LE, Lyer S, Chaurio R, Tietze R, Löhneysen S, Schorn C, Herrmann M and Alexiou C: Magnetic drug targeting reduces the chemotherapeutic burden on circulating leukocytes. Int J Mol Sci. 14:7341–7355. 2013. View Article : Google Scholar : PubMed/NCBI
36	Zhu Y, Li J, Li W, Zhang Y, Yang X, Chen N, Sun Y, Zhao Y, Fan C and Huang Q: The biocompatibility of nanodiamonds and their application in drug delivery systems. Theranostics. 2:302–312. 2012. View Article : Google Scholar : PubMed/NCBI
37	Man HB, Kim H, Kim HJ, Robinson E, Liu WK, Chow EK and Ho D: Synthesis of nanodiamond-daunorubicin conjugates to overcome multidrug chemoresistance in leukemia. Nanomedicine. 10:359–369. 2014. View Article : Google Scholar :
38	Ghoneum A, Sharma S and Gimzewski J: Nano-hole induction by nanodiamond and nanoplatinum liquid, DPV576, reverses multidrug resistance in human myeloid leukemia (HL60/AR). Int J Nanomed. 8:2567–2573. 2013. View Article : Google Scholar
39	Grignani F, Testa U, Fagioli M, Barberi T, Masciulli R, Mariani G, Peschle C and Pelicci PG: Promyelocytic leukemia-specific PML-retinoic acid alpha receptor fusion protein interferes with erythroid differentiation of human erythroleukemia K562 cells. Cancer Res. 55:440–443. 1995.PubMed/NCBI
40	Imaizumi M, Suzuki H, Yoshinari M, Sato A, Saito T, Sugawara A, Tsuchiya S, Hatae Y, Fujimoto T, Kakizuka A, et al: Mutations in the E-domain of RARα portion of the PML/RARα chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia. Blood. 92:374–382. 1998.PubMed/NCBI
41	Kim DG, Jeong YI, Choi C, Roh SH, Kang SK, Jang MK and Nah JW: Retinol-encapsulated low molecular water-soluble chitosan nanoparticles. Int J Pharm. 319:130–138. 2006. View Article : Google Scholar : PubMed/NCBI
42	Fung TK and So CW: Overcoming treatment resistance in acute promyelocytic leukemia and beyond. Oncotarget. 4:1128–1129. 2013.PubMed/NCBI
43	Huang X, Jain PK, El-Sayed IH and El-Sayed MA: Gold nanoparticles: Interesting optical properties and recent applications in cancer diagnostics and therapy. Nanomedicine. 2:681–693. 2007. View Article : Google Scholar : PubMed/NCBI
44	Choi YE, Kwak JW and Park JW: Nanotechnology for early cancer detection. Sens Basel. 10:428–455. 2010. View Article : Google Scholar
45	Radwan SH and Azzazy HM: Gold nanoparticles for molecular diagnostics. Expert Rev Mol Diagn. 9:511–524. 2009. View Article : Google Scholar : PubMed/NCBI
46	Hwang SH, Im SG, Hah SS, Cong VT, Lee EJ, Lee YS, Lee GK, Lee DH and Son SJ: Effects of upconversion nanoparticles on polymerase chain reaction. PLoS One. 8:e734082013. View Article : Google Scholar : PubMed/NCBI
47	Gormally E, Vineis P, Matullo G, Veglia F, Caboux E, Le Roux E, Peluso M, Garte S, Guarrera S, Munnia A, et al: TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: A prospective study. Cancer Res. 66:6871–6876. 2006. View Article : Google Scholar : PubMed/NCBI
48	Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, Anderson J, Bennett C, Goldman JM, Guilhot F, Kantarjian HM, Lichtin AE, et al: An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology. Blood. 94:1517–1536. 1999.PubMed/NCBI
49	Shet AS, Jahagirdar BN and Verfaillie CM: Chronic myelogenous leukemia: Mechanisms underlying disease progression. Leukemia. 16:1402–1411. 2002. View Article : Google Scholar : PubMed/NCBI
50	Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, Barbany G, Cazzaniga G, Cayuela JM, Cavé H, et al: Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia. 17:2318–2357. 2003. View Article : Google Scholar : PubMed/NCBI
51	Conde J, Doria G and Baptista P: Noble metal nanoparticles applications in cancer. J Drug Deliv. 2012:7510752012. View Article : Google Scholar
52	Baptista PV, Doria G, Quaresma P, Cavadas M, Neves CS, Gomes I, Eaton P, Pereira E and Franco R: Nanoparticles in molecular diagnostics. Prog Mol Biol Transl Sci. 104:427–488. 2011. View Article : Google Scholar : PubMed/NCBI
53	El-Metnawy WH, Mattar MM, El-Nahass YH, Samra MA, Abdelhamid HM, Abdlfattah RM and Hamed AR: Predictive value of pretreatment BCR-ABL (IS) transcript level on response to imatinib therapy in Egyptian patients with chronic phase chronic myeloid leukemia (CPCML). Int J Biomed Sci. 9:48–53. 2013.PubMed/NCBI
54	Kang Y, Hodges A, Ong E, Roberts W, Piermarocchi C and Paternostro G: Identification of drug combinations containing imatinib for treatment of BCR-ABL+ leukemias. PLoS One. 9:e1022212014. View Article : Google Scholar : PubMed/NCBI
55	Palamà IE, Coluccia AM and Gigli G: Uptake of imatinib-loaded polyelectrolyte complexes by BCR-ABL⁺ cells: A long-acting drug-delivery strategy for targeting oncoprotein activity. Nanomedicine. 9:2087–2098. 2014. View Article : Google Scholar
56	Jamieson CH: Chronic myeloid leukemia stem cells. Hematology Am Soc Hematol Educ Program. 2008:436–442. 2008. View Article : Google Scholar
57	Vilpo J, Hulkkonen J, Hurme M and Vilpo L: Surface membrane antigen expression changes induced in vitro by exogenous growth factors in chronic lymphocytic leukemia cells. Leukemia. 16:1691–1698. 2002. View Article : Google Scholar : PubMed/NCBI
58	Mukherjee P, Bhattacharya R, Bone N, Lee YK, Patra CR, Wang S, Lu L, Secreto C, Banerjee PC, Yaszemski MJ, et al: Potential therapeutic application of gold nanoparticles in B-chronic lymphocytic leukemia (BCLL): Enhancing apoptosis. J Nanobiotechnol. 5:42007. View Article : Google Scholar
59	Lee YK, Bone ND, Strege AK, Shanafelt TD, Jelinek DF and Kay NE: VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood. 104:788–794. 2004. View Article : Google Scholar : PubMed/NCBI
60	Bogusz J, Majchrzak A, Mędra A, Cebula-Obrzut B, Robak T and Smolewski P: Mechanisms of action of the anti-VEGF monoclonal antibody bevacizumab on chronic lymphocytic leukemia cells. Postepy Hig Med Dosw Online. 67:107–118. 2013. View Article : Google Scholar : PubMed/NCBI
61	Shanafelt TD, Gunderson H and Call TG: Commentary: Chronic lymphocytic leukemia - the price of progress. Oncologist. 15:601–602. 2010. View Article : Google Scholar
62	Żołnierczyk JD, Borowiak A, Błoński JZ, Cebula-Obrzut B, Rogalińska M, Kotkowska A, Wawrzyniak E, Smolewski P, Robak T and Kiliańska ZM: In vivo and ex vivo responses of CLL cells to purine analogs combined with alkylating agent. Pharmacol Rep. 65:460–475. 2013. View Article : Google Scholar : PubMed/NCBI
63	Yu B, Mao Y, Yuan Y, Yue C, Wang X, Mo X, Jarjoura D, Paulaitis ME, Lee RJ and Byrd JC: Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells. Biomaterials. 34:6185–6193. 2013. View Article : Google Scholar : PubMed/NCBI
64	Siddiqi T, Thomas SH and Chen R: Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma. Pharmgenomics Pers Med. 7:79–85. 2014.PubMed/NCBI
65	Zharov VP, Mercer KE, Galitovskaya EN and Smeltzer MS: Photothermal nanotherapeutics and nanodiagnostics for selective killing of bacteria targeted with gold nanoparticles. Biophys J. 90:619–627. 2006. View Article : Google Scholar
66	Kutok JL and Aster JC: Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma. J Clin Oncol. 20:3691–3702. 2002. View Article : Google Scholar : PubMed/NCBI
67	Heidegger S, Beer AJ, Geissinger E, Rosenwald A, Peschel C, Ringshausen I and Keller U: Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma. Onco Targets Ther. 7:1123–1127. 2014. View Article : Google Scholar : PubMed/NCBI
68	Zdzalik D, Dymek B, Grygielewicz P, Gunerka P, Bujak A, Lamparska-Przybysz M, Wieczorek M and Dzwonek K: Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma. J Cancer Res Clin Oncol. 140:589–598. 2014. View Article : Google Scholar : PubMed/NCBI
69	Zhao N, Bagaria HG, Wong MS and Zu Y: A nanocomplex that is both tumor cell-selective and cancer gene-specific for anaplastic large cell lymphoma. J Nanobiotechnol. 9:22011. View Article : Google Scholar
70	Zinzani PL, Vose JM, Czuczman MS, Reeder CB, Haioun C, Polikoff J, Tilly H, Zhang L, Prandi K, Li J, et al: Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: Subset analysis of the NHL-003 study. Ann Oncol. 24:2892–2897. 2013. View Article : Google Scholar : PubMed/NCBI
71	Desai M, Newberry K, Ou Z, Wang M and Zhang L: Lenalidomide in relapsed or refractory mantle cell lymphoma: Overview and perspective. Ther Adv Hematol. 5:91–101. 2014. View Article : Google Scholar : PubMed/NCBI
72	Pighi C, Gu TL, Dalai I, Barbi S, Parolini C, Bertolaso A, Pedron S, Parisi A, Ren J, Cecconi D, et al: Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling. Cell Oncol. 34:141–153. 2011. View Article : Google Scholar
73	Cely I, Yiv S, Yin Q, Shahidzadeh A, Tang L, Cheng J and Uckun FM: Targeting mantle cell lymphoma with anti-SYK nanoparticles. J Anal Oncol. 1:1–9. 2012.